Phase II trial of NX 1207 in patients with benign prostatic hyperplasia: 2-year follow-up study.
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2008
At a glance
- Drugs Fexapotide (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Sponsors Nymox Pharmaceutical Corporation
- 26 Sep 2008 Results from this development program presented at the American Urological Association Meeting in Chicago, as reported in a Nymox media release.
- 17 Sep 2008 Results presented at the 87th Annual Meeting of the South Central Section of the American Urological Association Meeting in September.
- 08 May 2008 Results after 3 years of follow-up reported in a Nymox Pharmaceutical Corporation media release.